AstraZenecaAZN
About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Employees: 94,300
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
191% more call options, than puts
Call options by funds: $855M | Put options by funds: $294M
62% more funds holding in top 10
Funds holding in top 10: 13 [Q4 2024] → 21 (+8) [Q1 2025]
58% more first-time investments, than exits
New positions opened: 147 | Existing positions closed: 93
40% more repeat investments, than reductions
Existing positions increased: 516 | Existing positions reduced: 368
9% more capital invested
Capital invested by funds: $34.1B [Q4 2024] → $37.3B (+$3.21B) [Q1 2025]
2% more funds holding
Funds holding: 1,202 [Q4 2024] → 1,222 (+20) [Q1 2025]
0.78% less ownership
Funds ownership: 33.12% [Q4 2024] → 32.35% (-0.78%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for AZN.
Financial journalist opinion
Based on 24 articles about AZN published over the past 30 days
